This document is a publication of a European patent application (EP4097219A1) from the EPO Patent Bulletin, specifically concerning "Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors." The applicant is ImmunityBio, Inc., and the publication date is March 11, 2026. This is a notification of a patent application, not a regulatory rule or enforcement action.

As this is a patent publication, there are no immediate compliance obligations or deadlines for regulated entities. Companies in the pharmaceutical and biotechnology sectors may wish to review the patent application for competitive intelligence or potential licensing opportunities. The designated states indicate broad European coverage for the patent if granted.